Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01646047
Other study ID # 20112190
Secondary ID
Status Completed
Phase N/A
First received July 3, 2012
Last updated January 20, 2015
Start date May 2012
Est. completion date September 2014

Study information

Verified date January 2015
Source ZeaVision, LLC
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This study will evaluate the effects of a novel multi-component dietary supplement on the visual function and retinal structure of patients with diabetes with both no diabetic retinopathy and mild to moderate diabetic retinopathy. This is a placebo-controlled trial and neither subjects nor examiners will know if any given subject is taking active supplement or placebo.

The hypothesis is that the supplement will improve visual function and retinal structure in subjects on active supplement


Description:

Adult patients with either type 1 or type 2 diabetes will be enrolled with baseline measurement of visual acuity, contrast sensitivity, color vision, threshold macular perimetry, macular pigment optical density, optical coherence tomography, glycosylated hemoglobin, blood lipids and serum vitamin D status. A multi-component dietary supplement containing ingredients currently available over the counter in the US will be taken for six months and repeat measurements of the above parameters obtained.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date September 2014
Est. primary completion date August 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- diabetes mellitus diagnosed at least 5 years

- age greater than or equal to 18 years

- English speaker

Exclusion Criteria:

- proliferative diabetic retinopathy or severe non-proliferative retinopathy

- clinically significant macular edema

- corrected visual acuity less than 20/30 in either eye

- diagnosis of other serious eye disease (glaucoma, age-related maculopathy)

- less than 18 years old

- non-English speaker

- no known allergy or sensitivity to any supplement ingredients

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
multi-component nutritional supplement capsules
two capsules containing nutritional supplements per day for 6 months (vitamin C, mixed tocopherols/tocotrienols, vitamin D, fish oil, lutein, zeaxanthin, pine bark extract, benfotiamine, green tea extract, curcumin)
multi-component dietary supplement
placebo capsules

Locations

Country Name City State
United States Chous Eye Care Associates Tacoma Washington

Sponsors (1)

Lead Sponsor Collaborator
ZeaVision, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in visual function Change in contrast sensitivity, color vision and macular perimetry thresholds At baseline and again at six months No
Secondary Changes in serum markers Changes in glycosylated hemoglobin, serum lipids, serum vitamin D (all subjects) and the serum inflammatory cytokine, tumor necrosis factor-alpha (subjects with retinopathy) At baseline and again at six months No
Secondary Changes in retinal structure Changes in optical coherence tomography and macular pigment optical density At baseline and again at 6 months No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04511715 - Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy Phase 2/Phase 3
Active, not recruiting NCT02388984 - Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy Phase 3
Not yet recruiting NCT01107132 - Blood-retinal Barrier Imaging and Neuropsychiatric Sequela in Type 2 Diabetes Mellitus N/A
Active, not recruiting NCT05681884 - Safety and Efficacy of Faricimab in Patients With NPDR Phase 2
Recruiting NCT06270836 - A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) Phase 3
Completed NCT02096874 - Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Phase 4
Completed NCT01853072 - Nepafenac Once Daily for Macular Edema - Study 1 Phase 3
Completed NCT01872611 - Nepafenac Once Daily for Macular Edema - Study 2 Phase 3
Not yet recruiting NCT04000789 - The Effect of Combination of Vitamin A, Vitamin E, Sodium Hyaluronate 0.15% Eye Drop Compared With Sodium Hyaluronate 0.1% Eye Drop to Tear Film Stability and Conjunctival Goblet Cells Density in Patient With Non-Proliferative Diabetic Retinopathy (NPDR), and Proliferative Diabetic Retinopathy (PDR) N/A
Active, not recruiting NCT05695417 - Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy Phase 1
Recruiting NCT05222633 - Anti-VEGF in Real-world
Completed NCT02062034 - Efficacy of Ubiquinone and Combined Antioxidant Therapy in Non-proliferative Diabetic Retinopathy Phase 2
Completed NCT02435862 - A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy Phase 2
Terminated NCT05066230 - A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) Phase 3
Recruiting NCT05393284 - Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy Phase 2
Completed NCT01571232 - Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema Phase 2